144.51MMarket Cap-1159P/E (TTM)
1.645High1.550Low944.34KVolume1.600Open1.600Pre Close1.50MTurnover1.37%Turnover RatioLossP/E (Static)90.32MShares8.59052wk High0.42P/B110.45MFloat Cap1.53552wk Low--Dividend TTM69.03MShs Float32.645Historical High--Div YieldTTM5.94%Amplitude1.535Historical Low1.588Avg Price1Lot Size
Caribou Biosciences Stock Forum
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
The regulator found a proposed comparator arm of platinum-based immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation to be "acceptable," the compan...
No comment yet